1. 2022-RA-579-ESGO A phase II study assessing safety and efficacy of cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failure (CABOCOL study). (20th October 2022) Authors: Coquan, Elodie; Lequesne, Justine; Colomba, Emeline; Frenel, Jean-Sébastien; Abdeddaim, Cyril; D'Hondt, Véronique; Castera, Marie; Abadie-Lacourtoisie, Sophie; Dubot, Coraline; Brachet, Pierre-Emmanuel; Leconte, Alexandra; Clarisse, Bénédicte; Joly, Florence Journal: International journal of gynecological cancer Issue: Volume 32(2022)Supplement 2 Page Start: A14 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018. (April 2023) Authors: Bylicki, Olivier; Tomasini, Pascale; Radj, Gervais; Guisier, Florian; Monnet, Isabelle; Ricordel, Charles; Bigay-Game, Laurence; Geier, Margaux; Chouaid, Christos; Daniel, Catherine; Swalduz, Aurelie; Toffart, Anne-Claire; Doubre, Helene; Peloni, Jean-Michel; Moreau, Diane; Subtil, Fabien; Grella... Journal: European journal of cancer Issue: Volume 183(2023) Page Start: 38 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗